TCT Video: Stone reveals two-year outcomes for SPIRIT IV

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Click to play
TCT Video: SPIRIT IV Principal Investigator Gregg W. Stone, MD

WASHINGTON, D.C.—Principal Investigator Gregg W. Stone, MD, explains the two-year outcomes of the SPIRIT IV trial, comparing the Xience V drug-eluting stent (Abbott) to the Taxus drug-eluting stent (Boston Scientific) for a primary endpoint of target lesion failure. He presented the results as a late-breaking clinical trial at the annual conference of Transcatheter Cardiovascular Therapeutics (TCT) Sept. 23. He comments that these results will continue to affect clinical practice, as “not all stents are created equal.”